Newron Pharmaceuticals S.p.A. (0QOI.L)

CHF 8.22

(0.24%)

Total Assets Summary of Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.'s latest annual total assets in 2023 was 25.86 Million EUR , down -30.46% from previous year.
Newron Pharmaceuticals S.p.A.'s latest quarterly total assets in 2024 Q2 was 24.93 Million EUR , down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported annual total assets of 37.19 Million EUR in 2022, down -26.33% from previous year.
Newron Pharmaceuticals S.p.A. reported annual total assets of 50.48 Million EUR in 2021, down -1.39% from previous year.
Newron Pharmaceuticals S.p.A. reported quarterly total assets of 25.86 Million EUR for 2023 FY, down -30.46% from previous quarter.
Newron Pharmaceuticals S.p.A. reported quarterly total assets of 31.49 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Assets Chart of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Historical Annual Total Assets of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Year	Total Assets	Total Assets Growth
2023	25.86 Million EUR	-30.46%
2022	37.19 Million EUR	-26.33%
2021	50.48 Million EUR	-1.39%
2020	51.19 Million EUR	-15.08%
2019	60.28 Million EUR	0.48%
2018	59.99 Million EUR	-17.84%
2017	73.02 Million EUR	29.04%
2016	56.59 Million EUR	27.51%
2015	44.38 Million EUR	19.71%
2014	37.07 Million EUR	17.26%
2013	31.61 Million EUR	-29.18%
2012	44.64 Million EUR	229.11%
2011	13.56 Million EUR	-29.09%
2010	19.13 Million EUR	-54.1%
2009	41.67 Million EUR	-31.16%
2008	60.54 Million EUR	-13.97%
2007	70.36 Million EUR	-18.33%
2006	86.15 Million EUR	266.67%
2005	23.49 Million EUR	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	24.93 Million EUR	0.0%
2023 FY	25.86 Million EUR	-30.46%
2023 Q2	31.49 Million EUR	0.0%
2023 Q4	25.86 Million EUR	0.0%
2022 Q2	43.54 Million EUR	0.0%
2022 FY	37.19 Million EUR	-26.33%
2022 Q4	37.19 Million EUR	0.0%
2021 Q4	50.48 Million EUR	0.0%
2021 Q2	39.88 Million EUR	0.0%
2021 FY	50.48 Million EUR	-1.39%
2020 Q4	51.19 Million EUR	0.0%
2020 FY	51.19 Million EUR	-15.08%
2020 Q2	57.83 Million EUR	0.0%
2019 Q2	59.83 Million EUR	0.0%
2019 Q4	60.28 Million EUR	0.0%
2019 FY	60.28 Million EUR	0.48%
2018 FY	59.99 Million EUR	-17.84%
2018 Q2	65.07 Million EUR	0.0%
2018 Q4	59.99 Million EUR	0.0%
2017 Q4	73.02 Million EUR	0.0%
2017 FY	73.02 Million EUR	29.04%
2017 Q2	57.32 Million EUR	0.0%
2016 Q2	38.71 Million EUR	0.0%
2016 FY	56.59 Million EUR	27.51%
2016 Q4	56.59 Million EUR	0.0%
2015 Q2	55.67 Million EUR	0.0%
2015 FY	44.38 Million EUR	19.71%
2015 Q4	44.38 Million EUR	0.0%
2014 Q4	37.07 Million EUR	0.0%
2014 FY	37.07 Million EUR	17.26%
2014 Q2	44.62 Million EUR	0.0%
2013 Q2	37.1 Million EUR	0.0%
2013 Q4	31.61 Million EUR	0.0%
2013 FY	31.61 Million EUR	-29.18%
2012 Q2	27.86 Million EUR	0.0%
2012 Q4	44.64 Million EUR	0.0%
2012 FY	44.64 Million EUR	229.11%
2011 Q2	19 Million EUR	0.0%
2011 Q4	13.56 Million EUR	0.0%
2011 FY	13.56 Million EUR	-29.09%
2010 Q2	28.82 Million EUR	0.0%
2010 Q4	19.13 Million EUR	0.0%
2010 FY	19.13 Million EUR	-54.1%
2009 FY	41.67 Million EUR	-31.16%
2009 Q4	41.67 Million EUR	0.0%
2008 FY	60.54 Million EUR	-13.97%
2007 FY	70.36 Million EUR	-18.33%
2006 FY	86.15 Million EUR	266.67%
2005 FY	23.49 Million EUR	0.0%

Peer Total Assets Comparison of Newron Pharmaceuticals S.p.A.

Name	Total Assets	Total Assets Difference
Relief Therapeutics Holding AG	76.39 Million CHF	66.14%
Tecan Group AG	2.07 Billion CHF	98.753%
Santhera Pharmaceuticals Holding AG	109.62 Million CHF	76.406%
Basilea Pharmaceutica AG	173.28 Million CHF	85.073%
Bachem Holding AG	1.68 Billion CHF	98.463%
Siegfried Holding AG	1.86 Billion CHF	98.61%
Molecular Partners AG	198.35 Million CHF	86.96%